Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Should we have concerns with generic versus brand antimicrobial drugs? A review of issues

Identifieur interne : 001508 ( Main/Exploration ); précédent : 001507; suivant : 001509

Should we have concerns with generic versus brand antimicrobial drugs? A review of issues

Auteurs : Michael A. Veronin [États-Unis]

Source :

RBID : ISTEX:04F6BDE8BA1262586DF27BF94C1DAC1D4442BD69

English descriptors

Abstract

Objectives  To explore the issues involving generic versus brand antimicrobial drug products and provide an overview of assessments of equivalence and their potential relevance to health outcomes. Methods  In April and May 2010, literature searches were performed in MEDLINE and EMBASE for studies involving antimicrobial drug products that convey equivalence or non‐equivalence of generic and brand‐name drugs. Key findings  Sixty‐six studies involving antibiotics, antifungals, antivirals and antimalarials were identified for analysis. The types of studies were categorized into microbial assays, pharmaceutical assays, bioequivalence and those that assess clinical endpoints. Studies varied markedly on equivalence measures between generic and brand drug products. Thirty‐four of 66 (52%) were primarily bioequivalency studies with 30 of 34 (88%) demonstrating positive outcomes for equivalency. Two of 22 studies (9%) involved microbial and/or pharmaceutical assays for quality assurance testing and presented the largest disparity in equivalence. Ten studies compared outcomes of a clinical nature and concluded no significant difference in outcome between generic and brand products. Ten of 66 (15%) studies were published before 2000 and 11 (17%) were conducted in the USA. Conclusions  In the USA, it is unlikely that use of generic antibiotics and antimicrobials pose a problem for patients with infectious diseases, where quality safeguards exist and patients are informed when generic substitution occurs. However, with expansion of international markets and questionable drug supply chains – particularly with the advent of the internet – consumers and providers should be aware of drug product quality differences that may impact patient outcomes.

Url:
DOI: 10.1111/j.1759-8893.2011.00059.x


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Should we have concerns with generic versus brand antimicrobial drugs? A review of issues</title>
<author>
<name sortKey="Veronin, Michael A" sort="Veronin, Michael A" uniqKey="Veronin M" first="Michael A." last="Veronin">Michael A. Veronin</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:04F6BDE8BA1262586DF27BF94C1DAC1D4442BD69</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1111/j.1759-8893.2011.00059.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-S9S9CRX2-P/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001E14</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E14</idno>
<idno type="wicri:Area/Istex/Curation">001E14</idno>
<idno type="wicri:Area/Istex/Checkpoint">000484</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000484</idno>
<idno type="wicri:doubleKey">1759-8885:2011:Veronin M:should:we:have</idno>
<idno type="wicri:Area/Main/Merge">001510</idno>
<idno type="wicri:Area/Main/Curation">001508</idno>
<idno type="wicri:Area/Main/Exploration">001508</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main">Should we have concerns with generic versus brand antimicrobial drugs? A review of issues</title>
<author>
<name sortKey="Veronin, Michael A" sort="Veronin, Michael A" uniqKey="Veronin M" first="Michael A." last="Veronin">Michael A. Veronin</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Social, Behavioral and Administrative Sciences, Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas</wicri:regionArea>
<placeName>
<region type="state">Texas</region>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Journal of Pharmaceutical Health Services Research</title>
<title level="j" type="alt">JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH</title>
<idno type="ISSN">1759-8885</idno>
<idno type="eISSN">1759-8893</idno>
<imprint>
<biblScope unit="vol">2</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="135">135</biblScope>
<biblScope unit="page" to="150">150</biblScope>
<biblScope unit="page-count">16</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2011-09">2011-09</date>
</imprint>
<idno type="ISSN">1759-8885</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1759-8885</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Acceptance ranges</term>
<term>Acyclovir</term>
<term>Antibacterial activity</term>
<term>Antibiotic</term>
<term>Antimicrobial</term>
<term>Antimicrobial agents</term>
<term>Antimicrobial drug products</term>
<term>Arzneimittelforschung</term>
<term>Assay</term>
<term>Assoc thai</term>
<term>Azithromycin</term>
<term>Bioavailability</term>
<term>Bioequivalence</term>
<term>Bioequivalence studies</term>
<term>Bioequivalence study</term>
<term>Bioequivalence testing</term>
<term>Bioequivalent</term>
<term>Brand antimicrobial drug products</term>
<term>Brand antimicrobial drugs</term>
<term>Brand antimicrobial drugs michael</term>
<term>Brand product</term>
<term>Brand products</term>
<term>Case report</term>
<term>Clarithromycin</term>
<term>Clin</term>
<term>Clin pharmacol</term>
<term>Clinical endpoints</term>
<term>Clinical outcomes</term>
<term>Cmax</term>
<term>Comparative bioavailability</term>
<term>Comparative bioavailability study</term>
<term>Crossover</term>
<term>Crossover design</term>
<term>Crossover study</term>
<term>Diagn microbiol</term>
<term>Dissolution properties</term>
<term>Dissolution testing</term>
<term>Dosage forms</term>
<term>Drug administration</term>
<term>Drug products</term>
<term>Drug quality</term>
<term>Equivalency</term>
<term>Funding</term>
<term>Funding source</term>
<term>Generic</term>
<term>Generic antibiotics</term>
<term>Generic drug</term>
<term>Generic drugs</term>
<term>Generic formulations</term>
<term>Generic products</term>
<term>Generic substitution</term>
<term>Healthy adult volunteers</term>
<term>Healthy subjects</term>
<term>Healthy thai volunteers</term>
<term>Healthy volunteers</term>
<term>Hplc</term>
<term>Hplc assay</term>
<term>Human subjects</term>
<term>Information source</term>
<term>Innovator</term>
<term>Innovator product</term>
<term>International markets</term>
<term>Intravenous</term>
<term>Irma lerma rangel college</term>
<term>Literature searches</term>
<term>Male volunteers</term>
<term>Microbial</term>
<term>Microbial assays</term>
<term>Oral formulations</term>
<term>Parameter</term>
<term>Pharmaceutical</term>
<term>Pharmaceutical assays</term>
<term>Pharmaceutical health services research</term>
<term>Pharmacokinetic</term>
<term>Pharmacol</term>
<term>Plasma concentrations</term>
<term>Plasma drug concentrations</term>
<term>Plasma samples</term>
<term>Positive outcomes</term>
<term>Randomized</term>
<term>Single dose</term>
<term>Tablet</term>
<term>Tetracycline</term>
<term>Texas health science center</term>
<term>Thai</term>
<term>Therapeutic equivalence</term>
<term>Tmax</term>
<term>Tobramycin</term>
<term>Vancomycin</term>
<term>Veronin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Objectives  To explore the issues involving generic versus brand antimicrobial drug products and provide an overview of assessments of equivalence and their potential relevance to health outcomes. Methods  In April and May 2010, literature searches were performed in MEDLINE and EMBASE for studies involving antimicrobial drug products that convey equivalence or non‐equivalence of generic and brand‐name drugs. Key findings  Sixty‐six studies involving antibiotics, antifungals, antivirals and antimalarials were identified for analysis. The types of studies were categorized into microbial assays, pharmaceutical assays, bioequivalence and those that assess clinical endpoints. Studies varied markedly on equivalence measures between generic and brand drug products. Thirty‐four of 66 (52%) were primarily bioequivalency studies with 30 of 34 (88%) demonstrating positive outcomes for equivalency. Two of 22 studies (9%) involved microbial and/or pharmaceutical assays for quality assurance testing and presented the largest disparity in equivalence. Ten studies compared outcomes of a clinical nature and concluded no significant difference in outcome between generic and brand products. Ten of 66 (15%) studies were published before 2000 and 11 (17%) were conducted in the USA. Conclusions  In the USA, it is unlikely that use of generic antibiotics and antimicrobials pose a problem for patients with infectious diseases, where quality safeguards exist and patients are informed when generic substitution occurs. However, with expansion of international markets and questionable drug supply chains – particularly with the advent of the internet – consumers and providers should be aware of drug product quality differences that may impact patient outcomes.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Texas</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Texas">
<name sortKey="Veronin, Michael A" sort="Veronin, Michael A" uniqKey="Veronin M" first="Michael A." last="Veronin">Michael A. Veronin</name>
</region>
<name sortKey="Veronin, Michael A" sort="Veronin, Michael A" uniqKey="Veronin M" first="Michael A." last="Veronin">Michael A. Veronin</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001508 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001508 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:04F6BDE8BA1262586DF27BF94C1DAC1D4442BD69
   |texte=   Should we have concerns with generic versus brand antimicrobial drugs? A review of issues
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021